Status:
COMPLETED
Strive Cardio for Endometrial Cancer Survivors
Lead Sponsor:
Jess S. Gorzelitz
Conditions:
Endometrial Cancer
Cardiovascular Diseases
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
STRIVE Cardio is a 12-week exercise intervention study with the goal to improve functional fitness and cardiovascular health for women who have completed treatment for non-metastatic endometrial cance...
Detailed Description
STRIVE Cardio is a distance-based exercise study for women who have completed treatment for non-metastatic endometrial cancer within the last five years and are currently in remission. The interventi...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Willing and able to provide written informed consent
- Willing to comply with study procedures and available for the duration of the study
- Fluent in spoken and written English
- Women 18 years of age or older
- Documented diagnosis of Type I, stage I-IIIc endometrial cancer within the past 5 years
- Completion of current cytotoxic treatment for endometrial cancer
- Technology access (phone call access, broadband internet, Wi-Fi) for tele coaching
- Comfort and willingness to use technology (videoconferencing) throughout the study for coaching
- Pass the Physical Activity Readiness Questionnaire (PAR-Q)
- Medical clearances given by their primary provider / oncologist (if indicated by the PAR-Q)
- Exclusion Criteria
- Absolute contraindications to exercise (i.e., acute myocardial infarction, severe orthopedic or musculoskeletal limitations)
- History of previous myocardial infarction, ischemia, or hemorrhagic stroke
- Medically documented history of heart disease including heart valve disease, coronary artery disease, heart failure, peripheral artery disease, aortic disease, pericardial disease, cerebrovascular disease, or deep vein thrombosis
- Medical documentation of treatment-resistant hypertension OR taking ≥2 medications to treat hypertension
- Medically documented history of cardiovascular disease including (but not limited to): bypass surgery, stent procedures, bypass grafts, or coronary angioplasty
- Medically documented or self-reported type 1 diabetes (insulin-dependents)
- Prescriptions for or use of semaglutide (GLP-1 agonists) including name brands: Ozempic, Wegovy or Mounjaro
- Current or recent (within last 3 months) use of hormone replacement therapy (HRT)
- Evidence of recurrent or metastatic disease
- Currently performing resistance training ≥2 days per week
- Currently exceeding 150 minutes of at least moderate intensity exercise per week
- Report of chest pain, shortness of breath, fainting, or angina pectoris
- Self-reported history of falling, fall risk
- Have physical disability that would limit range of motion through exercises such as sitting, standing and inability to walk one block
- Plans to move from the area
- Enrolled in another clinical trial or has used of any investigational drugs, biologics, or devices within 30 days prior to study enrollment
- Self-reported tobacco use in last 7 days, current smoking, current tobacco use including e-cigarettes and vaping devices
- Not suitable for study participation due to other reasons at the discretion of the investigator
Exclusion
Key Trial Info
Start Date :
July 23 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 17 2025
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT06534008
Start Date
July 23 2024
End Date
November 17 2025
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iowa
Iowa City, Iowa, United States, 52242